Zhejiang Orient Gene Biotech's (SHA:688298) subsidiaries received medical device registration certificates for three detection kits, according to a Shanghai Stock Exchange disclosure on Wednesday.
The devices are hepatitis B virus nucleic acid detection kit (fluorescence PCR method), and pepsinogen I and II detection kits (time-resolved fluorescence immunochromatography).
The certificate for hepatitis B kit is valid until Dec. 29, 2029, while those for the pepsinogen kits are valid until Dec. 23, 2029, the disclosure added.
Shares of the company closed over 3% lower.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。